Cytokine-induced viral purging - Role in viral pathogenesis

Current Opinion in Microbiology

Volumn 2, Issue 4, 1999, Pages 388-391

  Guidotti, Luca G ^a   Chisari, Francis V ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; CYTOKINE;

ANTIGEN SPECIFICITY; IMMUNE RESPONSE; IMMUNE SYSTEM; NONHUMAN; REVIEW; TARGET CELL; VIRUS INFECTION; VIRUS REPLICATION;

EID: 0033179072     PISSN: 13695274     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1369-5274(99)80068-X     Document Type: Review

References (53)

1. Shresta S, Pham CT, Thomas DA, Graubert TA, Ley TJ: How do cytotoxic lymphocytes kill their targets? Curr Opin Immunol 1998, 10:581-587.
2. Kagi D, Ledermann B, Burki K, Seiler P, Odermatt B, Olsen J, Podack ER, Zinkernagel R, Hengartner H: Cytotoxicity mediated by T cells and natural killer cells is greatly impaired in perforin-deficient mice. Nature 1994, 369:31-37.
3. Walsh CM, Matloubian M, Liu C-C, Ueda R, Kurahara CG, Christensen JL, Huang MT, Young JD-E, Ahmed R, Clark WR: Immune function in mice lacking the perform gene. Proc Natl Acad Sci USA 1994, 91:10854-10858.
4. Rossi CP, McAllister A, Tanguy M, Kagi D, Brahic M: Theiler's virus infection of perforin-deficient mice. J Virol 1998, 72:4515-4519.
5. + T cells clear influenza virus by perform or Fas-dependent processes. J Immunol 1997, 159:5197-5200.
6. Holterman AX, Rogers K, Edelmann K, Koelle DM, Corey L, Wilson CB: An important role for major histocompatibility complex class I-restricted T cells, and a limited role for gamma interferon, in protection of mice against lethal herpes simplex virus infection. J Virol 1999, 73:2058-2063.
7. Guidotti LG, Chisari FV: To kill or to cure: Options in host defense against viral infection. Curr Opin Immunol 1996, 8:478-483.
8. Guidotti LG, Rochford R, Chung L, Shapiro M, Purcell R, Chisari FV: Viral clearance without destruction of infected cells during acute HBV infection. Science 1999, 284:825-829. In this study, hepatitis B virus (HBV) was shown to largely disappear from the liver and the blood of acutely infected chimpanzees long before the peak of T cell infiltration and most of the liver disease. This demonstrated that noncytopathic antiviral mechanisms contribute to viral clearance during acute viral hepatitis by purging HBV replicative intermediates from the cytoplasm and covalently closed circular viral DNA from the nucleus of infected cells.
9. Guidotti LG, Ishikawa T, Hobbs MV, Matzke B, Schreiber R, Chisari FV: Intracellular inactivation of the hepatitis B virus by cytotoxic T lymphocytes. Immunity 1996, 4:25-36.
10. Cavanaugh VJ, Guidotti LG, Chisari FV: Interleukin-12 inhibits hepatitis B virus replication in HBV transgenic mice. J Virol 1997, 71:3236-3243.
11. Guidotti LG, Borrow P, Hobbs MV, Matzke B, Gresser I, Oldstone MBA, Chisari FV: Viral cross talk: Intracellular inactivation of the hepatitis B virus during an unrelated viral infection of the liver. Proc Natl Acad Sci USA 1996, 93:4589-4594.
12. Cavanaugh VJ, Guidotti LG, Chisari FV: Inhibition of hepatitis B virus replication during adenovirus and cytomegalovirus infections in HBV transgenic mice. J Virol 1998, 72:2630-2637.
13. Selin LK, Varga SM, Wong IC, Welsh RM: Protective heterologous antiviral immunity and enhanced immunopathogenesis mediated by memory T cell populations. J Exp Med 1998, 188:1705-1715.
14. Benihoud K, Saggio I, Opolon P, Salone B, Amiot F, Connault E, Chianale C, Dautry F, Yeh P, Perricaudet M: Efficient, repeated adenovirus-mediated gene transfer in mice lacking both tumor necrosis factor alpha and lymphotoxin alpha. J Virol 1998, 72:9514-9525.
15. Zhang HG, Zhou T, Yang P, Edwards CK 3rd, Curiel DT, Mountz JD: Inhibition of tumor necrosis factor alpha decreases inflammation and prolongs adenovirus gene expression in lung and liver. Hum Gene Ther 1998, 9:1875-1884.
16. Tay CH, Yu LY, Kumar V, Mason L, Ortaldo JR, Welsh RM: The role of LY49 NK cell subsets in the regulation of murine cytomegalovirus infections. J Immunol 1999, 162:718-726.
17. Biron CA: Role of early cytokines, including alpha and beta interferons (IFN- alpha/beta), in innate and adaptive immune responses to viral infections. Semin Immunol 1998, 10:383-390.
18. Lin MT, Hinton DR, Stohlman SA: Mechanisms of viral clearance in perforin-deficient mice. Adv Exp Med Biol 1998, 440:431-436.
19. Parra B, Hinton DR, Marten NW, Bergmann CC, Lin MT, Yang CS, Stohlman SA: IFN-gamma is required for viral clearance from central nervous system oligodendroglia. J Immunol 1999, 162:1641-1647.
20. Horwitz MS, Krahl T, Fine C, Lee J, Sarvetnick N: Protection from lethal coxsackievirus-induced pancreatitis by expression of gamma interferon. J Virol 1999, 73:1756-1766.
21. Gebhard JR, Perry CM, Harkins S, Lane T, Mena I, Asensio VC, Campbell IL, Whitton JL: Coxsackievirus B3-induced myocarditis: Perforin exacerbates disease, but plays no detectable role in virus clearance. Am J Pathol 1998, 153:417-428.
22. Guilhot S, Guidotti LG, Chisari FV: Interleukin-2 downregulates hepatitis B virus gene expression in transgenic mice by a post-transcriptional mechanism. J Virol 1993, 67:7444-7449.
23. Tsui LV, Guidotti LG, Ishikawa T, Chisari FV: Post-transcriptional clearance of hepatitis B virus RNA by cytotoxic T lymphocyte-activated hepatocytes. Proc Natl Acad Sci USA 1995, 92:12398-12402.
24. Heise T, Guidotti LG, Cavanaugh VJ, Chisari FV: Hepatitis B virus RNA-binding proteins associated with cytokine-induced clearance of viral RNA from the liver of transgenic mice. J Virol 1999, 73:474-481.
25. Heise T, Guidotti LG, Chisari FV: La autoantigen specifically recognizes a predicted stem-loop in hepatitis B virus RNA. J Virol 1999, 73:5767-5776.
26. Tuttleman JS, Pourcel C, Summers J: Formation of the pool of covalently closed circular viral DNA in hepadnavirus-infected cells. Cell 1986, 47:451-460.
27. Bock CT, Schranz R Schroder CH, Zentgraf H: Hepatitis B virus genome is organized into nucleosomes in the nucleus of the infected cell. Virus Genes 1994, 8:215-229.
28. Newbold JE, Xin H, Tencza M, Sherman G, Dean J, Bowden S, Locarnini S: The covalently closed duplex form of the hepadnavirus genome exists in situ as a heterogeneous population of viral minichromosomes. J Virol 1995, 69:3350-3357.
29. Moraleda G, Saputelli J, Aldrich CE, Averett D, Condreay L, Mason WS: Lack of effect of antiviral therapy in nondividing hepatocyte culture on the closed circular DNA of woodchuck hepatitis virus. J Virol 1997, 71:9292-9299.
30. Fourel I, Cullen JM, Saputelli J, Aldrich CE, Schaffer R Averett DR, Pugh J, Mason WS: Evidence that hepatocyte turnover is required for rapid clearance of duck hepatitis B virus during antiviral therapy of chronically infected ducks. J Virol 1994, 68:8321-8330.
31. Kalvakolanu DV, Borden EC: An overview of the interferon system: Signal transduction and mechanisms of action. Cancer Invest 1996, 14:25-53.
32. Der SD, Zhou A, Williams BR, Silverman RH: Identification of genes differentially regulated by interferon alpha, beta, or gamma using oligonucleotide arrays. Proc Natl Acad Sci USA 1998, 95:15623-15628.
33. Silverman RH: Fascination with 2-5A-dependent RNase: A unique enzyme that functions in interferon action. J Interferon Res 1994, 14:101-104.
34. Maitra RK, Silverman RH: Regulation of human immunodeficiency virus replication by 2′,5′-oligoadenylate-dependent RNase L. J Virol 1998, 72:1146-1152. Over-expression of RNAse L is shown to profoundly inhibit HIV replication in vitro.
35. Li XL, Blackford JA, Hassel BA: RNase L mediates the antiviral effect of interferon through a selective reduction in viral RNA during encephalomyocarditis virus infection. J Virol 1998, 72:2752-2759. Over-expression of RNAse L is shown to selectively reduce the intracellular content of encephalomyocarditis virus in vitro.
36. Diaz-Guerra M, Rivas C, Esteban M: Inducible expression of the 2-5A synthetase/RNase L system results in inhibition of vaccinia virus replication. Virology 1997, 227:220-228.
37. Haller O, Frese M, Kochs G: Mx proteins: Mediators of innate resistance to RNA viruses. Rev Sci Tech 1998, 17:220-230.
38. Kochs G, Trost M, Janzen C, Haller O: MxA GTPase: Oligomerization and GTP-dependent interaction with viral RNP target structures. Methods 1998, 15:255-263.
39. Reiss CS, Komatsu T: Does nitric oxide play a critical role in viral infections? J Virol 1998, 72:4547-4551. A comprehensive and critical review of the role of nitric oxide as an antiviral agent.
40. Saura M, Zaragoza C, McMillan A, Quick RA, Hohenadl C, Lowenstein JM, Lowenstein CJ: An antiviral mechanism of nitric oxide: Inhibition of a viral protease. Immunity 1999, 10:21-28. The first paper that describes a viral target for the antiviral activity of nitric oxide. A viral protease from coxsackievirus was identified as the target of nitric oxide.
41. Borrow P, Oldstone MBA: Lymphocytic choriomeningitis virus. In Viral Pathogenesis. Edited by Nathanson N. Lippincott-Raven: Philadelphia; 1997:593-627.
42. Guidotti LG, Borrow P, Brown A, McClary H, Koch R, Chisari FV: Noncytopathic clearance of lymphocytic choriomeningitis virus from the hepatocyte. J Exp Med 1999, 189:1555-1564. Persistent lymphocyte choriomeningitis virus (LCMV) infection is cleared from the hepatocyte noncytopathically when inflammatory cytokines are induced in the liver by antigen-nonspecific stimuli. In contrast, LCMV is not cleared from intrahepatic nonparenchymal cells or splenocytes indicating that, unlike the hepatocyte, these cells do not produce the factors required to inactivate LCMV.
43. Muller U, Steinhoff U, Reis LF, Hemmi S, Pavlovic J, Zinkernagel RM, Aguet M: Functional role of type I and type II interferons in antiviral defense. Science 1994, 264:1918-1921.
44. Leist TP, Eppler M, Zinkernagel RM: Enhanced virus replication and inhibition of lymphocytic choriomeningitis virus disease in anti-gamma interferon-treated mice. J Virol 1989, 63:2813-2819.
45. Wille A, Gessner A, Lother H, Lehmann-Grube F: Mechanism of recovery from acute virus infection. VIII. Treatment of lymphocytic choriomeningitis virus-infected mice with anti-interferon-gamma monoclonal antibody blocks generation of virus-specific cytotoxic T lymphocytes and virus elimination. Eur J Immunol 1989, 19:1283-1288.
46. Moskophidis D, Battegay M, Bruendler M-A, Laine E, Gresser I, Zinkernagel R: Resistance of lymphocytic choriomeningitis virus to alpha/beta interferon and gamma interferon. J Virol 1994, 68:1951-1955.
47. Lehmann Grube F, Assmann U, Loliger C, Moskophidis D, Lohler J: Mechanism of recovery from acute virus infection. I. Role of T lymphocytes in the clearance of lymphocytic choriomeningitis virus from spleens of mice. J Immunol 1985, 134:608-615.
48. Gegin C, Lehmann-Grube F: Control of acute infection with lymphocytic choriomeningitis virus in mice that cannot present an immunodominant viral cytotoxic T lymphocyte epitope. J Immunol 1992, 149:3331-3338.
49. Tishon A, Lewiski H, Rall G, VonHerrath M, Oldstone MBA: An essential role for type 1 interferon-γ in terminating persistent viral infection. Virology 1995, 212:244-250.
50. Tay CH, Welsh RM: Distinct organ-dependent mechanisms for the control of murine cytomegalovirus infection by natural killer cells. J Virol 1997, 71:267-275.
51. Kundig TM, Hengartner H, Zinkernagel RM: T cell-dependent IFN-γ exerts an antiviral effect in the central nervous system but not in peripheral solid organs. J Immunol 1993, 150:2316-2321.
52. Michalak TI, Pasquinelli C, Guilhot S, Chisari FV: Hepatitis B virus persistence after recovery from acute viral hepatitis. J Clin Invest 1994, 93:230-239.
53. Rehermann B, Ferrari C, Pasquinelli C, Chisari FV: The hepatitis B virus persists for decades after patients' recovery from acute viral hepatitis despite active maintenance of a cytotoxic T lymphocyte response. Nat Med 1996, 2:1104-1108.